NCT04952818View on ClinicalTrials.gov

The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine

CompletedOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

January 1, 2020

Primary Completion Date

March 1, 2020

Study Completion Date

March 1, 2020

Conditions
Spinal Tumor
Interventions
DIAGNOSTIC_TEST

RANK/RANKL(RANK: Receptor Activator of Nuclear factor Kappa-Β /RANKL:Receptor Activator of Nuclear factor Kappa-Β Ligand)

Immunohistochemical staining was performed using the following antibodies: anti-RANK antibody from Bioss Company (No.bs-2695R) and anti-RANKL antibody from Abcam (No.ab222215).

Trial Locations (1)

100089

Peking University third hospital, Beijing

All Listed Sponsors
lead

Peking University Third Hospital

OTHER

NCT04952818 - The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine | Biotech Hunter | Biotech Hunter